Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.
IPO Year: 2011
Exchange: AMEX
Website: smartvest.com
Electromed delivers eighth consecutive quarter of year-over-year revenue and profit growth, while continuing to invest in strategic growth initiatives Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended September 30, 2024 ("Q1 FY 2025"). Q1 FY 2025 Financial Highlights Net revenue increased 19.0% to $14.7 million in Q1 FY 2025, from $12.3 million in the first quarter of the prior fiscal year. Gross margin was 78.3% of net revenues, compared to 77.1% in the first quarter of the prior fiscal year. Operating income increased to $1.9 million or 13.2% of revenue compared to $0
Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will release its financial results for the fiscal 2025 first quarter ended September 30, 2024, on November 12, 2024 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: https://viavid.webcasts.com/starthere.jsp?ei=
Key hire will drive the Company's market development and therapy adoption initiatives Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced the appointment of Peter Horwich as Vice President, Marketing. Mr. Horwich, an accomplished marketing veteran, brings over 20 years of experience in driving commercial growth in the Medical Technology market to Electromed. Prior to joining Electromed, Horwich directed Global Strategic Marketing for Respiratory Therapies at Abiomed (now J&J MedTech), a Medical Device manufacturer of extracorporeal membrane oxygenation (ECMO) lung recovery systems, where he was responsible for global marketing
Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that effective as of September 11, 2024, its board of directors authorized the repurchase of up to $5.0 million of Electromed common stock. The new authorization follows the exhaustion of Electromed's previous share repurchase authorization in the fourth quarter of fiscal 2024, as previously reported. The timing and amount of share repurchases pursuant to the authorization, if any, will be determined by management based on market conditions and other considerations. Repurchases may be made from time to time on the open market at prevailing market prices, in privately negotiate
Record Q4 and full year financial results Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ("Q4 FY 2024") and full year ("FY 2024") ended June 30, 2024. Q4 FY 2024 Financial Highlights Net revenues increased 9.0% to a record $14.8 million in Q4 FY 2024, from $13.6 million in the fourth quarter of the prior fiscal year. Gross margin was 76.2% of revenue, compared to 76.8% in the fourth quarter of the prior fiscal year. Operating income increased by 56.3% to a record $2.3 million or 15.7% of revenue, compared with $1.5 million or 11.0% of revenue in the fourth quarter of the p
Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2024 fourth quarter ended June 30, 2024, on August 27, 2024 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (877) 407-0789 (Domestic) or (201) 689-8562 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Electromed Q4 Fiscal 2024 Webcast F
Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that Jim Cunniff, President and Chief Executive Officer, and Brad Nagel, Chief Financial Officer, are scheduled to attend the Canaccord Genuity 44th Annual Global Growth Conference being held in Boston on August 13-15, 2024. Electromed's management team will present at 2:30 p.m. Eastern Time on Wednesday, August 14, 2024. A link to the live and archived webcast of the event will be available on the Electromed website under Events & Presentations. You can also access the live webcast here. In advance of the event, Electromed has published an updated investor
Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that Jim Cunniff, President and Chief Executive Officer, and Brad Nagel, Chief Financial Officer, are scheduled to attend the 2024 Sidoti June Small-Cap Virtual Conference on June 12-13, 2024. Electromed's management team will present at 1:45 p.m. Eastern Time on Wednesday, June 12, 2024. A live and archived webcast of the event will be available on the Electromed website under Events & Presentations. You can also access the live webcast directly, here. About Electromed, Inc. Electromed, Inc. manufactures, markets, and sells products that provide airway c
Growth initiatives drive record revenue Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended March 31, 2024 ("Q3 FY 2024"). Q3 FY 2024 Financial Highlights Net revenues increased 15% to a record $13.9 million in Q3 FY 2024, from $12.1 million in the third quarter of the prior fiscal year. Gross margins were 75% of net revenues in the third quarters of both the current and prior fiscal years. Operating income increased by 54% to $1,841,000 or 13% of revenue, compared with $1,196,000 or 10% of revenue in the third quarter of the prior fiscal year. Net income was $1,493,00
Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2024 third quarter ended March 31, 2024, on May 7, 2024 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: https://viavid.webcasts.
4 - Electromed, Inc. (0001488917) (Issuer)
4 - Electromed, Inc. (0001488917) (Issuer)
4 - Electromed, Inc. (0001488917) (Issuer)
4 - Electromed, Inc. (0001488917) (Issuer)
4 - Electromed, Inc. (0001488917) (Issuer)
4 - Electromed, Inc. (0001488917) (Issuer)
4 - Electromed, Inc. (0001488917) (Issuer)
4 - Electromed, Inc. (0001488917) (Issuer)
4 - Electromed, Inc. (0001488917) (Issuer)
4 - Electromed, Inc. (0001488917) (Issuer)
4 - Electromed, Inc. (0001488917) (Issuer)
4 - Electromed, Inc. (0001488917) (Issuer)
4 - Electromed, Inc. (0001488917) (Issuer)
144 - Electromed, Inc. (0001488917) (Subject)
8-K - Electromed, Inc. (0001488917) (Filer)
10-Q - Electromed, Inc. (0001488917) (Filer)
8-K - Electromed, Inc. (0001488917) (Filer)
DEFA14A - Electromed, Inc. (0001488917) (Filer)
DEF 14A - Electromed, Inc. (0001488917) (Filer)
8-K - Electromed, Inc. (0001488917) (Filer)
10-K - Electromed, Inc. (0001488917) (Filer)
8-K - Electromed, Inc. (0001488917) (Filer)
8-K - Electromed, Inc. (0001488917) (Filer)
Key hire will drive the Company's market development and therapy adoption initiatives Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced the appointment of Peter Horwich as Vice President, Marketing. Mr. Horwich, an accomplished marketing veteran, brings over 20 years of experience in driving commercial growth in the Medical Technology market to Electromed. Prior to joining Electromed, Horwich directed Global Strategic Marketing for Respiratory Therapies at Abiomed (now J&J MedTech), a Medical Device manufacturer of extracorporeal membrane oxygenation (ECMO) lung recovery systems, where he was responsible for global marketing
Healthcare Executive Brings More Than 30 Years of Executive Experience and Commercial Success to Electromed Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced the appointment of Jim Cunniff as its new President and Chief Executive Officer (CEO), effective July 1, 2023. Mr. Cunniff will also join Electromed's Board of Directors. "We are pleased to announce the appointment of Jim Cunniff as president and CEO," said Lee Jones, Chair of the Board. "Jim is a proven executive with deep experience driving growth and profitability through excellence in products and services that benefit patients and support care teams. "As Kathle
Accomplished medical device leader to fill key strategic role Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that its Board of Directors has appointed Brad Nagel as the Company's Chief Financial Officer, effective November 14, 2022. Mr. Nagel brings to Electromed over fifteen years of financial leadership and strategic planning experience with Fortune 500 companies. Most recently, Mr. Nagel held the position of Divisional Chief Financial Officer of Global Lung Health and Visualization at Medtronic and was a key contributor in driving the unit's revenue growth. In that role, he served as the primary busine
Key appointment will guide the Company's strategic growth initiatives Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced the appointment of Christopher Holland as Chief Commercial Officer. Mr. Holland, an accomplished sales and marketing veteran, brings 30 years of experience in driving commercial growth in the Medical Technology market to Electromed. Prior to joining Electromed, Holland was the Vice President of Commercialization at Prosomnus Sleep Technologies, Inc., a Medical Device manufacturer of a mandibular advancement device for sleep apnea where he led new product introduction and revenue-growth init
SC 13D/A - Electromed, Inc. (0001488917) (Subject)
SC 13G/A - Electromed, Inc. (0001488917) (Subject)
SC 13G/A - Electromed, Inc. (0001488917) (Subject)
SC 13G/A - Electromed, Inc. (0001488917) (Subject)
SC 13G/A - Electromed, Inc. (0001488917) (Subject)
SC 13D/A - Electromed, Inc. (0001488917) (Subject)
SC 13G/A - Electromed, Inc. (0001488917) (Subject)
SC 13G/A - Electromed, Inc. (0001488917) (Subject)
SC 13D/A - Electromed, Inc. (0001488917) (Subject)
SC 13D - Electromed, Inc. (0001488917) (Subject)
Electromed (AMEX:ELMD) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.13 by 30.77 percent. This is a 41.67 percent increase over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $13.87 million which beat the analyst consensus estimate of $13.80 million by 0.51 percent. This is a 14.94 percent increase over sales of $12.07 million the same period last year.
Gainers Cogent Biosciences (NASDAQ:COGT) stock increased by 64.0% to $8.96 during Wednesday's regular session. The company's market cap stands at $771.2 million. Larimar Therapeutics (NASDAQ:LRMR) shares increased by 45.53% to $12.72. The company's market cap stands at $558.4 million. BioXcel Therapeutics (NASDAQ:BTAI) stock rose 35.2% to $3.33. The company's market cap stands at $101.0 million. Greenwich LifeSciences (NASDAQ:GLSI) stock moved upwards by 31.26% to $10.91. The company's market cap stands at $140.1 million. Electromed (AMEX:ELMD) stock rose 22.61% to $12.43. The market value of their outstanding shares is at $106.6 million. As per the news, the Q2 earnings report came out
Electromed (AMEX:ELMD) reported its Q2 earnings results on Tuesday, February 13, 2024 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Electromed beat estimated earnings by 90.0%, reporting an EPS of $0.19 versus an estimate of $0.1. Revenue was up $1.96 million from the same period last year. Past Earnings Performance Last quarter the company missed on EPS by $0.08 which was followed by a 2.09% increase in the share price the next day. Here's a look at Electromed's past performance: Quarter Q1 2024 Q4 2023 Q3 2023 Q2 2023 EPS Estimate 0.10 0.10 0.03 EPS Actual 0.02 0.12 0.12 0.11 Revenue Estimate 12.60M 12.80M 12.05M 11.05M Revenue Actual 12.32M
Electromed (AMEX:ELMD) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.10 by 90 percent. This is a 72.73 percent increase over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $13.69 million which beat the analyst consensus estimate of $13.30 million by 2.92 percent. This is a 16.71 percent increase over sales of $11.73 million the same period last year.
Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million. • Navios Maritime Partners (NYSE:NMM) is projected to report quarterly earnings at $2.62 per share on revenue of $334.79 million. • Restaurant Brands Intl (NYSE:QSR) is estimated to report quarterly earnings at $0.74 per share on revenue of $1.81 billion. • OrganiGram Holdings (NASDAQ:OGI) is projected to report quarterly loss at $0.13 per share on revenue of $37.77 million. • Hyatt Hotels (NYSE:H) is projected to report quarterly earnings at $0.29 per share on revenue of $1.86 billion. • InMode (NASDAQ:INMD) is likely to report quarterly
Electromed (AMEX:ELMD) is set to give its latest quarterly earnings report on Tuesday, 2024-02-13. Here's what investors need to know before the announcement. Analysts estimate that Electromed will report an earnings per share (EPS) of $0.10. Electromed bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Past Earnings Performance Last quarter the company missed EPS by $0.08, which was followed by a 2.09% increase in the share price
Electromed (AMEX:ELMD) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.10 by 80 percent. This is a 100 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $12.32 million which missed the analyst consensus estimate of $12.60 million by 2.19 percent. This is a 15.63 percent increase over sales of $10.66 million the same period last year.
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. • Ballard Power Systems (NASDAQ:BLDP) is expected to report quarterly loss at $0.13 per share on revenue of $26.20 million. • Melco Resorts and Enter (NASDAQ:MLCO) is likely to report quarterly earnings at $0.03 per share on revenue of $1.03 billion. • Consolidated Comms Hldgs (NASDAQ:CNSL) is expected to report quarterly loss at $0.37 per share on revenue of $274.23 million. • Sophia Genetics (NASDAQ:SOPH) is projected to report quarterly loss at $0.31 per share on revenue of $15.63 million. • Endeavor Gr Hldgs (NYSE:EDR) is estimated to report quarterly earnings
Electromed delivers eighth consecutive quarter of year-over-year revenue and profit growth, while continuing to invest in strategic growth initiatives Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended September 30, 2024 ("Q1 FY 2025"). Q1 FY 2025 Financial Highlights Net revenue increased 19.0% to $14.7 million in Q1 FY 2025, from $12.3 million in the first quarter of the prior fiscal year. Gross margin was 78.3% of net revenues, compared to 77.1% in the first quarter of the prior fiscal year. Operating income increased to $1.9 million or 13.2% of revenue compared to $0
Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will release its financial results for the fiscal 2025 first quarter ended September 30, 2024, on November 12, 2024 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: https://viavid.webcasts.com/starthere.jsp?ei=
Record Q4 and full year financial results Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ("Q4 FY 2024") and full year ("FY 2024") ended June 30, 2024. Q4 FY 2024 Financial Highlights Net revenues increased 9.0% to a record $14.8 million in Q4 FY 2024, from $13.6 million in the fourth quarter of the prior fiscal year. Gross margin was 76.2% of revenue, compared to 76.8% in the fourth quarter of the prior fiscal year. Operating income increased by 56.3% to a record $2.3 million or 15.7% of revenue, compared with $1.5 million or 11.0% of revenue in the fourth quarter of the p
Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2024 fourth quarter ended June 30, 2024, on August 27, 2024 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (877) 407-0789 (Domestic) or (201) 689-8562 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Electromed Q4 Fiscal 2024 Webcast F
Growth initiatives drive record revenue Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended March 31, 2024 ("Q3 FY 2024"). Q3 FY 2024 Financial Highlights Net revenues increased 15% to a record $13.9 million in Q3 FY 2024, from $12.1 million in the third quarter of the prior fiscal year. Gross margins were 75% of net revenues in the third quarters of both the current and prior fiscal years. Operating income increased by 54% to $1,841,000 or 13% of revenue, compared with $1,196,000 or 10% of revenue in the third quarter of the prior fiscal year. Net income was $1,493,00
Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2024 third quarter ended March 31, 2024, on May 7, 2024 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: https://viavid.webcasts.
Growth initiatives drive record revenue, improve margins and enhance operational efficiency Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended December 31, 2023 ("Q2 FY 2024"). Q2 FY 2024 Financial Highlights Net revenue increased 17% to a record $13.7 million in Q2 FY 2024, from $11.7 million in the second quarter of the prior fiscal year. Gross margins were 77% of revenue, compared to 74% in the second quarter of the prior fiscal year. Operating income was a record $2,263,000 or 16.5% of revenue, compared with $1,274,000 or 10.1% of revenue in the seco
Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2024 second quarter ended December 31, 2023, on February 13, 2024 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (877) 407-0789 (Domestic) or (201) 689-8562 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: https://viavid
Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended September 30, 2023 ("Q1 FY 2024"). Q1 FY 2024 Financial Highlights Net revenue increased 16% to $12.3 million in Q1 FY 2024, from $10.7 million in the first quarter of the prior fiscal year. Operating income was $142,000, compared with $44,000 in the first quarter of the prior fiscal year. Net income was $155,000 for the quarter, or $0.02 per diluted share, compared to $81,000, or $0.01 per diluted share in the first quarter of the prior fiscal year. "The first quarter of our fiscal year ending June 30,
Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2024 first quarter ended September 30, 2023, on Tuesday, November 7, 2023 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: https: